OQROGet OQRO Pro
Insider trade

Vertex Pharmaceuticals (VRTX)Officer sold ~$1.18M

Duncan Mckechnie, Officer at Vertex Pharmaceuticals, sold ~$1.18M of Vertex Pharmaceuticals shares.

~$1.18M
Approx. value · 2,410 sh @ $489.00
18K
Holds after · shares reported
Traded
Feb 25, 2026
Filed
Feb 26, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 23, 2024Congress · 1 personMembers of Congress: 2 purchases
  2. Jan 6, 2026Insider · Their largest sale since 2020Officer sold ~$4.39M of VRTX shares in the open market
  3. Jan 7, 2026InsiderOfficer sold ~$2.14M of VRTX shares in the open market
  4. Jan 29, 2026CongressDisclosed sale of VRTX — reported range $1,001 - $15,000
  5. Feb 11, 2026Insider · 5 peopleInsiders: 5 sales (~$3.5M)
  6. Feb 12, 2026Company filing · Form 8-K · ResultsReported its results
  7. Feb 12, 20265% stakeCapital Research Global Investors reported a passive stake (13G) of 6.8%
  8. Feb 13, 2026Insider · 3 peopleInsiders: 3 sales (~$1.4M)
  9. Feb 17, 2026Insider · 5 peopleInsiders: 5 sales (~$4.5M)
  10. Feb 18, 2026Insider · 5 peopleInsiders: 5 sales (~$2.0M)
  11. Feb 19, 2026Insider · 1 personInsiders: 8 sales (~$27.5M)
  12. Feb 25, 2026 · this disclosureInsiderOfficer sold ~$1.18M of VRTX shares in the open market

What came next

  1. Feb 25, 2026Insider · 7 peopleInsiders: 7 sales (~$3.4M)
  2. Feb 26, 2026InsiderOfficer sold ~$173K of VRTX shares in the open market
  3. Feb 27, 2026Insider · 2 peopleInsiders: 14 sales (~$20.9M)
  4. Mar 2, 2026InsiderOfficer sold ~$442K of VRTX shares in the open market
  5. Mar 4, 2026InsiderOfficer sold ~$1.16M of VRTX shares in the open market
  6. Mar 11, 2026InsiderOfficer sold ~$1.31M of VRTX shares in the open market
  7. Mar 13, 2026InsiderOfficer sold ~$1.12M of VRTX shares in the open market
  8. Mar 27, 2026FDAFDA drug approval: Alyftrek
  9. Mar 27, 2026FDAFDA drug approval: Trikafta (Copackaged)
  10. Mar 27, 2026FDAFDA drug approval: Trikafta (Copackaged)
  11. Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  12. Mar 27, 2026InsiderOfficer sold ~$1.05M of VRTX shares in the open market
  13. Apr 1, 2026InsiderOfficer sold ~$439K of VRTX shares in the open market
  14. Apr 28, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 28, 2026, Suketu Upadhyay informed the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”) of his decision not to stand for re-election as a director of the Company at the Company’s 2026 annual meeting of shareholders (the “2026 Annual Meeting”).”
  15. Apr 30, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  16. May 1, 2026InsiderOfficer sold ~$469K of VRTX shares in the open market
  17. May 4, 2026Company filing · Form 8-K · ResultsReported its results
  18. May 4, 2026InsiderDirector sold ~$135K of VRTX shares in the open market
  19. May 12, 2026Insider · Their largest sale since 2023Officer sold ~$3.14M of VRTX shares in the open market
  20. May 13, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On March 27, 2026, the Board of Directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") approved the Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan (the "2026 Plan"), which replaces the Vertex Pharmaceuticals Incorporated 2013 Stock and Option Plan, subject to shareholder approval.”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Vertex Pharmaceuticals

For Vertex Pharmaceuticals, OQRO holds 2 Congress trade reports and 42 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its VRTX page.

Other recent filings by Duncan Mckechnie, EVP, Chief Commercial Officer

The full history of Duncan Mckechnie, EVP, Chief Commercial Officer is on the profile page.

How this filing works

Other disclosures at Vertex Pharmaceuticals

Everything OQRO holds on this company is on its VRTX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data